Literature DB >> 36161259

Expected cost effectiveness of the fourth dose of COVID-19 vaccine against the omicron variant of COVID-19: a preliminary report.

Rujittika Mungmunpuntipantip1, Viroj Wiwanitkit2.   

Abstract

OBJECTIVES: COVID-19 immunization has been shown to be effective in the prevention of COVID-19. Traditionally, two doses of COVID-19 vaccines are required. Booster immunization is generally required when immunity has deteriorated.
METHODS: The effectiveness of the alternate boost immunization protocol is still unknown. The authors of this study used a cost-effectiveness analysis, which is a retrospective analysis on datasets on cost and effectiveness, to examine the projected cost-effectiveness of boosting COVID-19 vaccination by a fourth dose.
RESULTS: The cost-effectiveness of the fourth-dose COVID booster vaccine was found to be higher in this study.
CONCLUSION: It could imply that vaccinating against the current pandemic of the novel form, omicron, with the additional COVID-19 vaccine is a smarter idea. IJPPP
Copyright © 2022.

Entities:  

Keywords:  COVID-19; booster; dose; half; vaccine; variant

Year:  2022        PMID: 36161259      PMCID: PMC9490214     

Source DB:  PubMed          Journal:  Int J Physiol Pathophysiol Pharmacol        ISSN: 1944-8171


  21 in total

1.  Cost-Effectiveness Analysis in Radiology: A Systematic Review.

Authors:  Alice Zhou; David M Yousem; Matthew D Alvin
Journal:  J Am Coll Radiol       Date:  2018-07-26       Impact factor: 5.532

Review 2.  Cost-effectiveness analysis.

Authors:  T G Ganiats
Journal:  Prim Care       Date:  1995-06       Impact factor: 2.907

3.  Expected response to the additional third dose of COVID-19 vaccine based on different complete standard vaccination background.

Authors:  Sora Yasri; Viroj Wiwanitkit
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2022-02-15

Review 4.  COVID-19 vaccine: where are we now and where should we go?

Authors:  Saman Soleimanpour; Atieh Yaghoubi
Journal:  Expert Rev Vaccines       Date:  2021-02-17       Impact factor: 5.217

5.  Fourth dose of COVID-19 vaccines in Israel.

Authors:  Talha Khan Burki
Journal:  Lancet Respir Med       Date:  2022-01-11       Impact factor: 30.700

6.  Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.

Authors:  Yinon M Bar-On; Yair Goldberg; Micha Mandel; Omri Bodenheimer; Ofra Amir; Laurence Freedman; Sharon Alroy-Preis; Nachman Ash; Amit Huppert; Ron Milo
Journal:  N Engl J Med       Date:  2022-04-05       Impact factor: 91.245

7.  Certificate of need laws: a systematic review and cost-effectiveness analysis.

Authors:  Christopher J Conover; James Bailey
Journal:  BMC Health Serv Res       Date:  2020-08-14       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.